Teladoc Net Worth
Teladoc Net Worth Breakdown | TDOC |
Teladoc Net Worth Analysis
Teladoc's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Teladoc's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Teladoc's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Teladoc's net worth analysis. One common approach is to calculate Teladoc's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Teladoc's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Teladoc's net worth. This approach calculates the present value of Teladoc's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Teladoc's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Teladoc's net worth. This involves comparing Teladoc's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Teladoc's net worth relative to its peers.
Enterprise Value |
|
To determine if Teladoc is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Teladoc's net worth research are outlined below:
| Teladoc appears to be risky and price may revert if volatility continues | |
| Teladoc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.6 B. Net Loss for the year was (220.37 M) with profit before overhead, payroll, taxes, and interest of 1.66 B. | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: 2 Former Pandemic Darlings Eyeing a Big 2025 Turnaround - MarketBeat |
Teladoc Quarterly Good Will |
|
Teladoc uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Teladoc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Teladoc's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Teladoc's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Teladoc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Teladoc backward and forwards among themselves. Teladoc's institutional investor refers to the entity that pools money to purchase Teladoc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 3.5 M | Wellington Management Company Llp | 2024-06-30 | 2.5 M | Susquehanna International Group, Llp | 2024-06-30 | 2.1 M | Barclays Plc | 2024-06-30 | 2.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 2.1 M | Voloridge Investment Management, Llc | 2024-06-30 | 1.8 M | Assenagon Asset Management Sa | 2024-09-30 | 1.7 M | Man Group Plc | 2024-06-30 | 1.7 M | Qube Research & Technologies | 2024-06-30 | 1.7 M | Blackrock Inc | 2024-06-30 | 21.6 M | Vanguard Group Inc | 2024-09-30 | 17.4 M |
Follow Teladoc's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.55 B.Market Cap |
|
Project Teladoc's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.14) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.10) |
When accessing Teladoc's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Teladoc's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Teladoc's profitability and make more informed investment decisions.
Please note, the presentation of Teladoc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Teladoc's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Teladoc's management manipulating its earnings.
Evaluate Teladoc's management efficiency
Teladoc has return on total asset (ROA) of (0.0313) % which means that it has lost $0.0313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5165) %, meaning that it created substantial loss on money invested by shareholders. Teladoc's management efficiency ratios could be used to measure how well Teladoc manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.14. The current year's Return On Capital Employed is expected to grow to -0.06. At present, Teladoc's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 84.3 M, whereas Net Tangible Assets are projected to grow to (475.5 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.34 | 26.40 | |
| Tangible Book Value Per Share | (2.62) | (2.49) | |
| Enterprise Value Over EBITDA | 25.74 | 27.02 | |
| Price Book Value Ratio | 1.50 | 1.43 | |
| Enterprise Value Multiple | 25.74 | 27.02 | |
| Price Fair Value | 1.50 | 1.43 | |
| Enterprise Value | 4 B | 5.9 B |
The management team at Teladoc has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.7316 | Revenue 2.6 B | Quarterly Revenue Growth (0.03) | Revenue Per Share 15.333 | Return On Equity (0.52) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Teladoc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Teladoc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Teladoc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Teladoc Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Teladoc Earnings per Share Projection vs Actual
Teladoc Corporate Directors
| Sandra Fenwick | Independent Director | Profile | |
| Christopher Bischoff | Independent Director | Profile | |
| David Shedlarz | Independent Director | Profile | |
| William Frist | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teladoc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Teladoc Stock refer to our How to Trade Teladoc Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teladoc. If investors know Teladoc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teladoc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.78) | Revenue Per Share 15.333 | Quarterly Revenue Growth (0.03) | Return On Assets (0.03) | Return On Equity (0.52) |
The market value of Teladoc is measured differently than its book value, which is the value of Teladoc that is recorded on the company's balance sheet. Investors also form their own opinion of Teladoc's value that differs from its market value or its book value, called intrinsic value, which is Teladoc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teladoc's market value can be influenced by many factors that don't directly affect Teladoc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teladoc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teladoc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teladoc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.